温熱療法はMRIによる精度の高い温度モニターで治療の効果があがってきたことが
知られているが、
温熱療法と放射線療法の組み合わせで治療効果をあげている例がでてきた。
その報告は
Proceedings of the XXVII ICHS International Meeting, October 27-28, 2005, Florence, Italy.
Published in the German Journal of Oncology, (Deutsche Zeitschrift für Onkologie) 2006, 38: 116-122.
Alternative cancer treatment, alternative breast cancer treatment, alternative prostate cancer treatment.
THERMORADIOTHERAPY WITH CURATIVE INTENT - BREAST, HEAD AND NECK AND PROSTATE TUMORS
JAMES I. BICHER, M.D., NAZAR Al-BUSSAM, M.D. and RALPH S. WOLFSTEIN, M.D.
Valley Cancer Institute, Los Angeles, California U.S.A.
http://www.vci.org/thermoradiotherapy.htm
で以下のように結論づけられるという。
Conclusion: Protracted hyperfractionation of daily thermoradiotherapy
Decreases the radiation dose by 15 to 25%
Decreases the side effects of radiation therapy
Allows treating to effect using objective end point parameters (tumor markers, PET scans, MRI, etc.)
Accomplishes a high percentage of complete responses in superficial tumors
Accomplishes a high 5-year survival rate in the 80-90% range in early superficial tumors
Is potentially curative in early stage breast, head and neck and prostate cancers
知られているが、
温熱療法と放射線療法の組み合わせで治療効果をあげている例がでてきた。
その報告は
Proceedings of the XXVII ICHS International Meeting, October 27-28, 2005, Florence, Italy.
Published in the German Journal of Oncology, (Deutsche Zeitschrift für Onkologie) 2006, 38: 116-122.
Alternative cancer treatment, alternative breast cancer treatment, alternative prostate cancer treatment.
THERMORADIOTHERAPY WITH CURATIVE INTENT - BREAST, HEAD AND NECK AND PROSTATE TUMORS
JAMES I. BICHER, M.D., NAZAR Al-BUSSAM, M.D. and RALPH S. WOLFSTEIN, M.D.
Valley Cancer Institute, Los Angeles, California U.S.A.
http://www.vci.org/thermoradiotherapy.htm
で以下のように結論づけられるという。
Conclusion: Protracted hyperfractionation of daily thermoradiotherapy
Decreases the radiation dose by 15 to 25%
Decreases the side effects of radiation therapy
Allows treating to effect using objective end point parameters (tumor markers, PET scans, MRI, etc.)
Accomplishes a high percentage of complete responses in superficial tumors
Accomplishes a high 5-year survival rate in the 80-90% range in early superficial tumors
Is potentially curative in early stage breast, head and neck and prostate cancers